Cargando…

Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?

The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achie...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffaelli, Marco, Sessa, Luca, Mingrone, Geltrude, Bellantone, Rocco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467753/
https://www.ncbi.nlm.nih.gov/pubmed/26089694
http://dx.doi.org/10.2147/DMSO.S50659
_version_ 1782376408255823872
author Raffaelli, Marco
Sessa, Luca
Mingrone, Geltrude
Bellantone, Rocco
author_facet Raffaelli, Marco
Sessa, Luca
Mingrone, Geltrude
Bellantone, Rocco
author_sort Raffaelli, Marco
collection PubMed
description The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achieve the improvements in diabetic remission observed after bariatric-metabolic surgery. Several studies have demonstrated that bariatric-metabolic surgery is an effective treatment for type 2 diabetes when compared with conventional nonsurgical medical treatment. Because the best results are achievable in patients with a relatively short history of diabetes and less advanced controlled disease, the surgical option could be considered early, especially in morbid obese subjects (BMI ≥35 kg/m(2)) after failure of medical treatment. Patients with extensive weight loss are more likely to achieve type 2 diabetes remission after bariatric surgery. At present, Roux-en-Y gastric bypass seems the surgical procedure of choice because it has fewer risks than biliopancreatic diversion, and it is associated with higher weight loss and metabolic improvements compared with adjustable gastric banding. Recent evidences regarding the effectiveness of sleeve gastrectomy in diabetes remission have to be confirmed by controlled trials with longer follow-up.
format Online
Article
Text
id pubmed-4467753
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44677532015-06-18 Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose? Raffaelli, Marco Sessa, Luca Mingrone, Geltrude Bellantone, Rocco Diabetes Metab Syndr Obes Review The worldwide prevalence of type 2 diabetes is rising in association with an increasing frequency of overweight and obesity. Bariatric-metabolic procedures are considered as additional therapeutic options, allowing improved diabetes control in most patients. Multiple factors play in concert to achieve the improvements in diabetic remission observed after bariatric-metabolic surgery. Several studies have demonstrated that bariatric-metabolic surgery is an effective treatment for type 2 diabetes when compared with conventional nonsurgical medical treatment. Because the best results are achievable in patients with a relatively short history of diabetes and less advanced controlled disease, the surgical option could be considered early, especially in morbid obese subjects (BMI ≥35 kg/m(2)) after failure of medical treatment. Patients with extensive weight loss are more likely to achieve type 2 diabetes remission after bariatric surgery. At present, Roux-en-Y gastric bypass seems the surgical procedure of choice because it has fewer risks than biliopancreatic diversion, and it is associated with higher weight loss and metabolic improvements compared with adjustable gastric banding. Recent evidences regarding the effectiveness of sleeve gastrectomy in diabetes remission have to be confirmed by controlled trials with longer follow-up. Dove Medical Press 2015-06-08 /pmc/articles/PMC4467753/ /pubmed/26089694 http://dx.doi.org/10.2147/DMSO.S50659 Text en © 2015 Raffaelli et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Raffaelli, Marco
Sessa, Luca
Mingrone, Geltrude
Bellantone, Rocco
Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
title Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
title_full Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
title_fullStr Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
title_full_unstemmed Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
title_short Assessing the obese diabetic patient for bariatric surgery: which candidate do I choose?
title_sort assessing the obese diabetic patient for bariatric surgery: which candidate do i choose?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467753/
https://www.ncbi.nlm.nih.gov/pubmed/26089694
http://dx.doi.org/10.2147/DMSO.S50659
work_keys_str_mv AT raffaellimarco assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose
AT sessaluca assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose
AT mingronegeltrude assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose
AT bellantonerocco assessingtheobesediabeticpatientforbariatricsurgerywhichcandidatedoichoose